United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement

UNITED THERAPEUTICS Corp

TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).
Statistically significant improvements in secondary endpoints including time to first clinical worsening, K-BILD, and DLCO.
Safety profile consistent with prior Tyvaso studies; no new safety signals observed.
Company plans FDA meeting to discuss expedited review; TETON-1 data expected H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.